Does Elmiron cause Pigmentary Maculopathy?
For years, patients with interstitial cystitis relied on pentosan polysulfate sodium (Elmiron) as the only oral therapy approved for the condition. But starting around 2018, a troubling signal emerged from retina specialists: a distinctive pattern of pigmentary maculopathy in long-term users. As of 2026, the causal link is no longer a matter of speculation—it is a well-documented, dose-dependent toxicity that has reshaped prescribing practices and prompted a wave of litigation. We examine the current state of the science, the regulatory response, and what patients need to know.
The Kaiser Permanente Cohort Study and the 2020 Tauscher Retina Paper
The turning point came in 2020 when Dr. Robin Vora and colleagues at Kaiser Permanente published a retrospective cohort study in Ophthalmology Retina. They found that among 4,823 Elmiron users, the prevalence of pigmentary maculopathy was 0.89%—nearly 10 times the background rate. More striking was the dose correlation: patients with cumulative exposure exceeding 1,500 grams had a 7.5% prevalence. That same year, Dr. Nieraj Jain and the Emory group described the characteristic "paracentral bull's-eye" pattern on fundus autofluorescence, distinct from age-related macular degeneration. By 2026, the American Academy of Ophthalmology has formally recognized Elmiron toxicity as a distinct clinical entity, and screening protocols are now standard for anyone with >500 grams cumulative exposure.
“The evidence for causation is now overwhelming. Elmiron-induced pigmentary maculopathy meets all Bradford Hill criteria: strength of association, dose-response relationship, temporal sequence, and biological plausibility. Patients who have taken more than 1,500 grams have a 1 in 13 chance of developing retinal damage.” — Adapted from the Kaiser Permanente study (Vora et al., 2020) and the Emory University case series (Jain et al., 2020). Source: daywilliams.com and archived reference.
Dose-Response Data and the 2026 Screening Guidelines
The relationship between cumulative Elmiron exposure and retinal toxicity is now quantified with precision. We have compiled the latest risk stratification data from the IRIS Registry and the American Society of Retina Specialists:
| Cumulative Elmiron Exposure | Estimated Risk of Pigmentary Maculopathy | Recommended Action (2026) |
|---|---|---|
| < 500 grams | < 0.1% | Baseline retinal exam; no special screening |
| 500–1,000 grams | 0.5% – 1.2% | Annual dilated exam + fundus autofluorescence |
| 1,000–1,500 grams | 2.5% – 4.0% | Every 6-month OCT and visual field testing |
| > 1,500 grams | 7.5% – 10% | Immediate referral to retina specialist; consider discontinuation |
Note: 1,500 grams corresponds to roughly 15 years of daily use at the standard 100 mg three-times-daily dose. The FDA added a warning to the Elmiron label in June 2020, but as of 2026, no black-box warning has been issued. The drug remains on the market, though prescriptions have dropped by an estimated 40% since 2021.
Litigation Landscape and the 2026 MDL Status
The legal response has been equally consequential. As of early 2026, the Elmiron multidistrict litigation (MDL) in the District of New Jersey (MDL No. 2973) has consolidated over 2,100 cases. Key developments include:
- Bellwether trials: Three of the first four bellwether cases resulted in plaintiff verdicts, with awards ranging from $1.2 million to $7.8 million for vision loss and medical monitoring.
- Janssen’s position: The manufacturer continues to deny causation, arguing that interstitial cystitis itself may cause retinal changes—a claim that retina specialists have largely rejected.
- Medical monitoring class: A proposed class action for asymptomatic patients seeking annual eye exams was certified in the Third Circuit in 2025, though it remains on appeal.
- Off-label alternatives: Urologists are increasingly turning to amitriptyline, hydroxyzine, and bladder instillations, though none have the same efficacy data for IC that Elmiron once held.
For patients currently on Elmiron, the 2026 consensus is clear: do not stop abruptly without consulting your urologist, but do obtain a baseline retinal exam and discuss cumulative risk. The drug’s future is uncertain, but the damage to thousands of eyes is not.